Physician profile
Ramesh Kumar
NPI 1114000114
$3,456.53
in general payments reported to CMS, 2019-2025
17 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $54.58 · 2021: $60.98 · 2022: $463 · 2023: $861 · 2024: $549 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043 · Education: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.69 |
| Education | $305.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,903.74 | 2019-2025 | |
| Janssen Biotech, INC. | $554.58 | 2022-2025 | Tremfya |
| Amgen INC. | $345.17 | 2022-2025 | Otezla, Enbrel, Uplizna |
| Ucb, INC. | $196.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $135.68 | 2019 | |
| Nuvasive, INC. | $80.31 | 2023 | Xlif |
| E.R. Squibb & Sons, L.L.C. | $70.48 | 2019-2025 | Orencia |
| Celgene Corporation | $55.74 | 2019 | |
| Lilly USA, LLC | $27.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.39 | 2020 | |
| Emd Serono, INC. | $21.56 | 2019 | |
| Boston Scientific Corporation | $19.12 | 2019 | |
| Almatica Pharma LLC | $15.57 | 2025 | Loreev Xr |
| Organon LLC | $8.89 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.